“Treatment of Cancer Patients during the SARS-CoV2 Pandemic: Learnings and outlook after 18 months”
The Cancer Drug Development Forum held the second CDDF Live Webinar Series – Lessons Learnt from COVID-19: “Treatment of Cancer Patients during the SARS-CoV2 Pandemic: Learnings and outlook after 18 months” on Tuesday 13 July 2021 at 17:30-18:30 CEST. This webinar comprised a lecture given by Prof. Dr. Marie von Lilienfeld-Toal(Jena University Hospital, DE), followed by a discussion session moderated by Prof. Axel Glasmacher (CDDF).
Prof. Dr. Marie von Lilienfeld-Toal had given her first talk on “Treatment of Cancer Patients during the SARS-CoV2 Pandemic: Implications for Clinical Trials” at the CDDF webinar in April 2020. For this webinar, she presented and discussed learnings and outlook for clinical trials in oncology after 18 months from the outbreak of the global pandemic.
PREVIOUS WEBINARS ON COVID-19
- Prof. Marie von Lilienfeld-Toal’s first talk – Treatment of Cancer Patients during the SARS-CoV2 Pandemic: Implications for Clinical Trials ( April 2020)
- CDDF Live Webinar Series – Lessons Learnt from COVID-19:“A Cancer Institute’s experience in the operational cancer clinical trial performance during the COVID-pandemic”
- Prof. Axel Glasmacher (CDDF)
Prof. Marie von Lilienfeld-Toal is professor of Medicine at the University Clinic of Jena in Germany. Her clinical and scientific focus on haematological malignancies and Infectious Diseases in immunocompromised patients with a focus on virology. She is also the author of the “COVID-19 Guidelines of the German, Austrian and Swiss Societies of Haematology-Oncology” and “EHA SWG Infections in Hematology FAQ Recommendations.”
17:30 – 17:35 (CEST): Introduction (Prof. Axel Glasmacher)
17:35 – 18:00 (CEST): Lecture (Prof. Marie von Lilienfeld-Toal)
18:00 – 18:30 (CEST): Q&A / discussion session
RECORDING & POWERPOINT